Sign Out
No intravascular injection.
Equipment and drugs such as adrenaline and others should be available for first aid in case of severe allergic reaction. The recipients shall be observed for at least 30 minutes on site following injection.
In the following situation, this vaccine should be used cautiously: Subjects with thrombocytopenia or hemorrhagic disease, as intramuscular administration of this vaccine may cause bleeding; Subjects who are receiving immunosuppressive therapy or with immune deficiency disorder, as the immune response to this vaccine may be reduced. Inoculation should be postponed until the end of the treatment or to make sure the subject is well protected. For subjects with chronic immunodeficiency, even if the underlying illness may result in limited immune response, vaccination is nevertheless recommended; Subjects with uncontrolled epilepsy and other progressive nervous system disease.
Similar with other vaccines, this vaccine may not generate 100% protective efficacy for vaccine recipients.
Do not use the vaccine if it is abnormally turbid or the container shows crack.
When opening the container and injecting the vaccine, do not let disinfectant contact the vaccine.
Freezing is strictly forbidden. The vaccine shall be administered immediately after the container is opened.
The interval should be at least one month or more between vaccinating this vaccine and injecting immunoglobin, lest affecting the immune effect.
Effects on ability to drive and use machine: Not applicable.
